LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration
LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years.
The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial. LIGHTSITE IIIB will treat patients for 4 rounds of treatment over fourteen months. Sham patients in the previous study will be able to cross over and begin PBM treatment.
The LIGHTSITE IIIB extension trial follows the successfully completed LIGHTSITE III trial, which showed a sustained, mean increase in best corrected vision acuity (BCVA) letter score of >5.0 letters from baseline at the 13- and 24-month timepoints (p < 0.0001) using the Company’s Valeda ® Light Delivery System. The study demonstrated disease slowing benefits as fewer PBM-treated eyes progressed to new geographic atrophy (GA), a later disease stage that is associated with permanent loss of retinal tissue and scar. The 24-month optical coherence tomography (OCT) imaging of the retina indicated that only 6.8% of the PBM group had progressed to new GA, whereas 24% in the sham group developed new GA.
“Currently approved dry AMD treatments are limited to costly, invasive intravitreal injections targeting end stage disease that are not able to improve or sustain vision, unlike the results in the LIGHTSITE III trial,” stated Eleonora Lad, M.D., Ph.D., Vice-chair of Ophthalmology Clinical Research at Duke University School of Medicine. “The centers that participated in the LIGHTSITE III trial have reached out to study participants and received an overwhelming patient response to continue with the PBM treatments for an additional year. This is a testimonial about the potential impact of PBM for intermediate dry AMD patients.”
“The LIGHTSITE III patients that received the sham treatment continued to show disease progression. The open label study design will now follow the sham patients after receiving treatments and will continue to follow the PBM-treated patients for another year,” stated David Boyer, MD., Retina-Vitreous Associates Medical Group, Los Angeles, CA. “The ability to continue to treat and monitor these patients for another year should add to the knowledge and exciting results of sustaining vision and slowing disease progression as seen during the LIGHTSITE III trial.”
"The NIH clinical grant is substantial in providing up to $2.3M in funding to further establish a PBM non-invasive therapy for dry AMD patients in the U.S.,” stated Clark Tedford, Ph.D., President and CEO. “We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera as we bring the therapy to U.S. patients.”
AMD is a leading cause of vision loss for people aged 65 and older. Losing central vision can make it harder to see faces, drive, or do close-up work like cooking or fixing things around the house. The overall prevalence of AMD is estimated to increase 7-fold with age, from 4.2% in those aged 45–49 years, to 27.2% in those aged 80–85 years. Globally, the prevalence is estimated to increase by 20% between 2020 (195.6 million) and 2030 (243.3 million).
LumiThera, Inc. is a medical device company focused on diagnosing, treating, and monitoring ocular disease and damage including dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 65.
LumiThera’s flagship product, the Valeda® Light Delivery System, uses multiwavelength photobiomodulation to treat dry AMD patients. Valeda is CE Marked in the EU and is available in Europe and in countries in Latin America. Valeda is not yet approved by the Food & Drug Administration (FDA).
AdaptDx Pro® dark adaptation functional testing technology enables eye care professionals to detect and monitor AMD three years before clinical presentation. AdaptDx Pro is listed on the FDA’s Establishment Registration & Device Listing.
Diopsys ERG and VEP systems help eye care professionals analyze the entire pathway for visual and neuro-visual disorders. VEP is FDA-cleared. ERG and VEP are available in select countries outside of the USA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Senior Director, Marketing
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Higround and The Pokémon Company International Invite Fans to Explore Fan-Favorite Pokémon in New Collection5.12.2023 00:31:00 EET | Press release
In a new and special collaboration, Higround, a powerhouse within the lifestyle and gaming spheres, is teaming up with The Pokémon Company International to create an exciting collection that seamlessly blends the worlds of competitive gaming, and the beloved Pokémon franchise. This unique partnership introduces a carefully curated collection of gaming peripherals inspired by fan-favorite Pokémon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204512387/en/ Pokémon + Higround Blastoise Summit 65 Keyboard (Photo: Business Wire) Higround introduces its line of Pokémon-themed keyboards and additional accoutrement, offering fans a tactile way to connect with their favorite franchise. In this unique collection, the Base 65 and Summit 65 Keyboards take center stage. The Base 65 models, for the everyday adventurer, feature designs like the iconic Poké Ball and fan-favorite Pokémon, including Venusaur, Charizard, Blastoise, and Me
Gurobi 11.0 Delivers Global Nonlinear Solving, Speed Enhancements, Dynamic Distributed Tuning, and Enterprise Features4.12.2023 21:48:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 11.0. This advancement marks a significant step forward in solving real-world nonlinear problems with Gurobi. With Gurobi 11.0, users can quickly identify precise, globally optimal solutions to complex nonlinear problems—from domains such as chemical engineering, electricity flow, and price optimization. Additionally, this new version delivers a key enhancement to Gurobi’s popular tuning tool, enabling teams to share resources across multiple users and jobs when tuning. As with every major Gurobi release, users will experience a boost to Gurobi’s industry-leading solver speed. Compared to Gurobi 10.0, version 11.0 delivers the following performance improvements: Algorithm Speed-Up: Overall (>1 sec) Speed-Up: On Hard Models (>100sec) MILP 8.6% 12.4% MIQP 12.8% 22.8% Convex MIQCP 9.2% 18.2% Nonconvex MIQCP 133.4% (2.3x) 480.2% (5.8x) “For nonconvex problems, we achiev
Fitch Group Completes Acquisition of Bixby4.12.2023 21:46:00 EET | Press release
Fitch Group, a global leader in financial information services owned by Hearst, today announced that it has completed the acquisition of all the remaining stock it does not own of Bixby Research and Analytics (“Bixby”), a leading provider of credit information on private syndicated loan issuers. Earlier this year Fitch Ventures, the equity investment arm of Fitch Group, led Bixby’s Series A round. Bixby, founded by Brian Conroy, will become a wholly-owned subsidiary of Fitch Solutions and will be managed by CreditSights. Bixby will be incorporated into CreditSights’ leveraged finance product suite, which includes Covenant Review’s legal analysis, LevFin Insights’ news and data, and CreditSights’ fundamental research. Ted Niedermayer, President of Fitch Solutions, said: “The acquisition of Bixby is a natural next step as we continue to prioritize our leveraged finance offerings. Bixby’s data provides complementary insights to CreditSights, which bolsters our loan offering and also allow
SoftServe Named as a Challenger in 2023 Gartner Magic Quadrant for Custom Software Development Services, Worldwide4.12.2023 20:31:00 EET | Press release
SoftServe, a premier IT consulting and digital services provider, today announced it has been named by Gartner® as a Challenger in the 2023 Magic Quadrant™ for Custom Software Development Services, Worldwide. SoftServe was recognized for its ability to execute and completeness of vision. “SoftServe is recognized throughout the market as a preferred partner for some of the world’s leading technology providers and enterprises,” said Alex Chubay, SoftServe’s CTO. “Our approach involves a holistic perspective encompassing business acumen, user experience, cloud and data engineering, along with cutting-edge technologies – such as Generative AI – that enable our clients to build award-winning digital products and transform their businesses.” Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. For more than
Limited Libations, Innovative Blending, Escapism Elixirs and More are Shaping the Way That Consumers Drink in 2024, Based on the Bacardi Cocktail Trends Report4.12.2023 18:40:00 EET | Press release
Bacardi Limited, the world’s largest privately held international spirits company, releases its fifth annual Bacardi Cocktail Trends Report, anticipating the key trends that will redefine cocktail culture and the spirits business in 2024. The report, created in collaboration with strategic foresight consultancy, The Future Laboratory (TFL), draws on insights from Bacardi-led and external research, interviews with bartenders and insights from The Future Laboratory to share the themes that are transforming flavor preferences, drink formats, and cocktail experiences in the coming year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231202332985/en/ Find out what's in store for 2024 with the Bacardi Cocktail Trends Report. (Graphic: Business Wire) “As 2024 arrives, people are looking to settle into the unsettled – welcoming tastes of optimism into our reality. In this landscape, people are reshaping cocktail culture, infusing it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom